| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Neurocrine Biosciences INC (NBIX) has 18 insiders with recent SEC Form 4 filings, including 0 buys and 9 sells. NBIX is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 620.9K | $79.68M | - | |
| CEO | 140.4K | $18.02M | - | |
| Other | 52.8K | $6.77M | - | |
| Other | 46.8K | $6.00M | - | |
| Other | 26.9K | $3.45M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 3, 2017 | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 1,375 | $42.56 | $58,520.00 | -1.2% | |
| Feb 3, 2017 | Obrien Christopher Flint | Chief Medical Officer | Sell | 1,500 | $42.50 | $63,750.00 | -4.1% | |
| Feb 1, 2017 | Rastetter William H | Director | Sale+OE | 10,750 | $42.28 | $454,510.00 | -43.0% | |
| Jan 17, 2017 | Bozigian Haig P. | Chief Development Officer | Sell | 1,625 | $40.63 | $66,023.75 | -1.4% | |
| Jan 17, 2017 | Coughlin Timothy P | Chief Financial Officer | Sell | 1,750 | $40.65 | $71,137.50 | -1.3% | |
| Jan 17, 2017 | Gano Kyle | Chief Business Development Off | Sell | 1,625 | $40.65 | $66,056.25 | -2.7% | |
| Jan 17, 2017 | Gorman Kevin Charles | Chief Executive Officer | Sell | 3,750 | $40.65 | $152,437.50 | -1.5% | |
| Jan 17, 2017 | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 1,625 | $40.63 | $66,023.75 | -1.4% | |
| Jan 17, 2017 | Obrien Christopher Flint | Chief Medical Officer | Sell | 1,750 | $40.66 | $71,155.00 | -5.0% |